<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharma 101 - Pharmaceutical Fraud &#187; Ethics</title>
	<atom:link href="http://pharmaceutical-kickbacks.com/tag/ethics/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaceutical-kickbacks.com</link>
	<description>Information &#38; Insight On Qui Tam Lawsuits Based Upon Unlawful Kickbacks, Marketing &#38; Pricing Conduct.</description>
	<lastBuildDate>Fri, 16 Dec 2011 21:42:34 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2</generator>
		<item>
		<title>Progress and Deficiencies in the Registration of Clinical Trials</title>
		<link>http://pharmaceutical-kickbacks.com/progress-and-deficiencies-in-the-registration-of-clinical-trials/</link>
		<comments>http://pharmaceutical-kickbacks.com/progress-and-deficiencies-in-the-registration-of-clinical-trials/#comments</comments>
		<pubDate>Sat, 14 Feb 2009 20:00:42 +0000</pubDate>
		<dc:creator>Nolan and Auerbach</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Clinical trial]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[New England Journal of Medicine]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://pharmaceutical-kickbacks.com/?p=10</guid>
		<description><![CDATA[The New England Journal of Medicine just recently published an article which raises questions about the ethics and the science of increasingly conducting studies, or clinical trials, outside the United States — when the studies are meant to gather evidence for new drugs to gain approval in this country. The concept certainly raised the issue [...]]]></description>
			<content:encoded><![CDATA[<p>The New England Journal of Medicine just recently published an article which raises questions about the ethics and the science of increasingly conducting studies, or clinical trials, outside the United States — when the studies are meant to gather evidence for new drugs to gain approval in this country. The concept certainly raised the issue of whether there is increased <a href="http://www.whistleblowerfirm.com/pharmaceutical-fraud/" target="_blank" onclick="pageTracker._trackPageview('/outgoing/www.whistleblowerfirm.com/pharmaceutical-fraud/?referer=');">clinical trial fraud</a> outside of this country, to the extent there is  less oversight and/or ethics. See Ethical and Scientific Implications of the Globalization of Clinical Research, February 19, 2009.</p>
<p>To read more click on<br />
<a href="http://content.nejm.org/cgi/content/full/360/8/824" target="_blank" onclick="pageTracker._trackPageview('/outgoing/content.nejm.org/cgi/content/full/360/8/824?referer=');">http://content.nejm.org/cgi/content/full/360/8/824</a></p>
<div class="zemanta-pixie" style="margin-top: 10px; height: 15px;"><span class="zem-script more-related"><script src="http://static.zemanta.com/readside/loader.js" type="text/javascript"></script></span></div>
]]></content:encoded>
			<wfw:commentRss>http://pharmaceutical-kickbacks.com/progress-and-deficiencies-in-the-registration-of-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

